PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: LamdaGen Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Alion and LamdaGen Announce Collaboration to Accelerate Small Molecule Drug Development - Rapid identification of compounds to treat neurodegenerative diseases - Alion-Pharmaceuticals.com / LamdaGen.com
Alion and LamdaGen Announce Collaboration to Accelerate Small Molecule Drug Development

 

NewswireToday - /newswire/ - Menlo Park, CA, United States, 2011/02/22 - Rapid identification of compounds to treat neurodegenerative diseases - Alion-Pharmaceuticals.com / LamdaGen.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Alion Pharmaceuticals and LamdaGen Corporation announced today that the two biotechnology companies have entered into a Strategic Collaboration to identify and characterize small molecule inhibitors for the treatment of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s Disease, and Neuropathic Pain.

The Collaboration combines Alion’s proprietary computer aided drug design technology and methodologies with LamdaGen’s highly sensitive nano-sensor based bioanalytical systems to accelerate the identification of novel small molecule drug candidates to treat neurologic disorders.

“Recent efforts between our two organizations have led to the validated activity of several Alion compounds directed against targets of therapeutic value in Alzheimer’s disease. With combined use of our respective technologies, we have demonstrated that protein/peptide interactions can be regulated with our small molecule inhibitors. This has important implications for the identification of new therapeutic drugs, which makes this early stage discovery and validation activity very exciting, ” stated Allan Bates, President of Alion.
The companies are in discussion with several pharmaceutical companies regarding the utilization of their integrated discovery technologies for use in specific drug discovery and development programs.

About Alion

Alion Pharmaceuticals (alion-pharmaceuticals.com) is a computational chemistry company employing proprietary CADD and biophysical methodologies to accelerate the discovery and development of small molecule therapeutics.

About LamdaGen

LamdaGen Corporation (lamdagen.com) is a rapidly growing biosensor company utilizing proprietary nano-based metamaterials to facilitate improved testing and analyses for drug discovery and development, as well as diagnostic applications.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: LamdaGen Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Alion and LamdaGen Announce Collaboration to Accelerate Small Molecule Drug Development

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Nicholas Virca, COO - LamdaGen.com 
650-571-5816 collaboration[.]alion-pharmaceuticals.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any LamdaGen Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From LamdaGen Corporation / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  1Click Games





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)